Crinetics Pharmaceuticals (CRNX) Proxy filing summary

Executive summary

• Vertex Pharmaceuticals will acquire all outstanding shares of Crinetics Pharmaceuticals for $85 per share in cash, valuing the deal at approximately $10 billion, or $8.8 billion net of estimated cash acquired.

• The transaction was unanimously approved by both companies' boards and is expected to close in Q3 2026, pending regulatory and shareholder approvals.

• The acquisition brings PALSONIFY, a once-daily oral therapy for acromegaly, and atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia, into Vertex's portfolio.

• Vertex expects the deal to accelerate revenue growth, with combined peak annual revenue potential of over $5 billion from these assets.

• Financing will be through a mix of cash and $4.5 billion in committed bridge financing from major banks.

Voting matters and shareholder proposals

• Crinetics shareholders will vote on the adoption of the merger agreement at a special meeting to be scheduled after SEC review of the proxy statement.

• Approval by a majority of outstanding shares is required for the merger to proceed.

Board of directors and corporate governance

• The Crinetics board unanimously determined the transaction is fair and in the best interests of shareholders, recommending approval.

• The board received fairness opinions from Leerink Partners LLC and J.P. Morgan Securities LLC.

• Directors of Crinetics will resign at the effective time of the merger.